Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Schmidt-Erfurth, Ursula; Eldem, Bora; Guymer, Robyn; Korobelnik, Jean-Francois; Schlingemann, Reinier; Axer-Siegel, Ruth; Wiedemann, Peter; Simader, Christian; Gekkieva, Margarita; Weichselberger, Andreas

doi:10.1016/j.ophtha.2010.09.004

Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Atıf İçin Kopyala

Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J., Schlingemann R. O., Axer-Siegel R., ...Daha Fazla

OPHTHALMOLOGY, cilt.118, sa.5, ss.831-839, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 118 Sayı: 5
Basım Tarihi: 2011
Doi Numarası: 10.1016/j.ophtha.2010.09.004
Dergi Adı: OPHTHALMOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.831-839
Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).